NCT02322047 - Prazosin and Naltrexone (PaN) Study for Veterans With Alcohol Use Disorders | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 3, 2015

Primary Completion Date

October 10, 2018

Study Completion Date

October 10, 2018

Conditions

Alcohol Use DisorderPosttraumatic Stress Disorder (PTSD)

Interventions

DRUG

Prazosin

Prazosin Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM

DRUG

Naltrexone

Naltrexone Dosing Days 1-42: 50mg @ 9PM

DRUG

Placebo (Prazosin)

Placebo Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM

DRUG

Placebo (Naltrexone)

Placebo Dosing Days 1-42: 50mg @ 9PM

Trial Locations (1)

98108

VA Puget Sound Healthcare System, Seattle

All Listed Sponsors

collaborator

United States Department of Defense

FED

collaborator

VA Puget Sound Health Care System

FED

lead

Seattle Institute for Biomedical and Clinical Research

OTHER